OBJECTIVE: Indirect acute lung injury is associated with high morbidity and mortality. However, the underlying pathophysiology is only marginally understood, and so far no pathophysiologic-based remedy exists. We hypothesized that apoptosis of lung epithelial cells is a pathophysiological relevant process in the development of indirect acute lung injury and that it should be accessible to a siRNA-based therapeutic intervention in vivo. DESIGN: Prospective, randomized, controlled animal study. SETTING: Basic science laboratory of a university affiliated level one trauma center. SUBJECTS: Male C3H/HeN mice, 8 wks old, n = 121. INTERVENTIONS: First, siRNA sequences to knock-down caspase-3 expression at a RNA and protein level were evaluated in vitro. Then, C3H/HeN mice were subjected to hemorrhagic shock, after which they received either a caspase-3 siRNA or a control/nonsense siRNA. Subsequently, they were then subjected to polymicrobial sepsis (induced by cecal ligation and puncture). MEASUREMENTS AND MAIN RESULTS: Twelve and 24 hrs after sepsis, increased lung epithelial apoptosis was observed, as evidenced by active caspase-3 Western blotting, caspase-3, TUNEL-, and M-30 immunohistochemistry. Hallmarks of acute lung injury, such as increased concentrations of pulmonary cytokines/chemokines, lung protein leakage, myeloperoxidase activity, and altered lung histology, were evident in response to these insults. The single intratracheal instillation of caspase-3 siRNA not only attenuated lung apoptosis and inflammation but also ameliorated the development of acute lung injury in treated mice. Most interestingly, this experimental therapeutic approach markedly improved 10-day survival of hemorrhaged septic mice. CONCLUSIONS: Apoptosis of lung epithelial cells is a relevant pathomechanism in the development of hemorrhage-induced indirect septic acute lung injury, and caspase-3 appears to be a valuable therapeutic target accessible by siRNA treatment in vivo.
OBJECTIVE: Indirect acute lung injury is associated with high morbidity and mortality. However, the underlying pathophysiology is only marginally understood, and so far no pathophysiologic-based remedy exists. We hypothesized that apoptosis of lung epithelial cells is a pathophysiological relevant process in the development of indirect acute lung injury and that it should be accessible to a siRNA-based therapeutic intervention in vivo. DESIGN: Prospective, randomized, controlled animal study. SETTING: Basic science laboratory of a university affiliated level one trauma center. SUBJECTS: Male C3H/HeN mice, 8 wks old, n = 121. INTERVENTIONS: First, siRNA sequences to knock-down caspase-3 expression at a RNA and protein level were evaluated in vitro. Then, C3H/HeN mice were subjected to hemorrhagic shock, after which they received either a caspase-3 siRNA or a control/nonsense siRNA. Subsequently, they were then subjected to polymicrobial sepsis (induced by cecal ligation and puncture). MEASUREMENTS AND MAIN RESULTS: Twelve and 24 hrs after sepsis, increased lung epithelial apoptosis was observed, as evidenced by active caspase-3 Western blotting, caspase-3, TUNEL-, and M-30 immunohistochemistry. Hallmarks of acute lung injury, such as increased concentrations of pulmonary cytokines/chemokines, lung protein leakage, myeloperoxidase activity, and altered lung histology, were evident in response to these insults. The single intratracheal instillation of caspase-3 siRNA not only attenuated lung apoptosis and inflammation but also ameliorated the development of acute lung injury in treated mice. Most interestingly, this experimental therapeutic approach markedly improved 10-day survival of hemorrhaged septic mice. CONCLUSIONS: Apoptosis of lung epithelial cells is a relevant pathomechanism in the development of hemorrhage-induced indirect septic acute lung injury, and caspase-3 appears to be a valuable therapeutic target accessible by siRNA treatment in vivo.
Authors: Carl D Novina; Michael F Murray; Derek M Dykxhoorn; Paul J Beresford; Jonathan Riess; Sang-Kyung Lee; Ronald G Collman; Judy Lieberman; Premlata Shankar; Phillip A Sharp Journal: Nat Med Date: 2002-06-03 Impact factor: 53.440
Authors: T Kataoka; R C Budd; N Holler; M Thome; F Martinon; M Irmler; K Burns; M Hahne; N Kennedy; M Kovacsovics; J Tschopp Journal: Curr Biol Date: 2000-06-01 Impact factor: 10.834
Authors: K Kuwano; R Kunitake; T Maeyama; N Hagimoto; M Kawasaki; T Matsuba; M Yoshimi; I Inoshima; K Yoshida; N Hara Journal: Am J Physiol Lung Cell Mol Physiol Date: 2001-02 Impact factor: 5.464
Authors: S Hashimoto; A Kobayashi; K Kooguchi; Y Kitamura; H Onodera; H Nakajima Journal: Am J Respir Crit Care Med Date: 2000-01 Impact factor: 21.405
Authors: Y Kitamura; S Hashimoto; N Mizuta; A Kobayashi; K Kooguchi; I Fujiwara; H Nakajima Journal: Am J Respir Crit Care Med Date: 2001-03 Impact factor: 21.405
Authors: Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler Journal: N Engl J Med Date: 2000-05-04 Impact factor: 91.245
Authors: G Matute-Bello; C W Frevert; W C Liles; M Nakamura; J T Ruzinski; K Ballman; V A Wong; C Vathanaprida; T R Martin Journal: Infect Immun Date: 2001-09 Impact factor: 3.441
Authors: Dina C Nacionales; Alex G Cuenca; Ricardo Ungaro; Lori F Gentile; Dallas Joiner; Minoru Satoh; Joanne Lomas-Neira; Alfred Ayala; Azra Bihorac; Matthew J Delano; Darwin N Ang; Philip A Efron Journal: Shock Date: 2012-12 Impact factor: 3.454
Authors: Rajan K Thakkar; Chun-Shiang Chung; Yaping Chen; Sean F Monaghan; Joanne Lomas-Neira; Daithi S Heffernan; William G Cioffi; Alfred Ayala Journal: Shock Date: 2011-08 Impact factor: 3.454
Authors: Sean F Monaghan; Rajan K Thakkar; Daithi S Heffernan; Xin Huang; Chun-Shiang Chung; Joanne Lomas-Neira; William G Cioffi; Alfred Ayala Journal: Ann Surg Date: 2012-01 Impact factor: 12.969
Authors: Elisabetta Liverani; Sarah A Tursi; William D Cornwell; Mark J Mondrinos; Shuang Sun; Bettina A Buttaro; Marla R Wolfson; Thomas J Rogers; Çagla Tükel; Laurie E Kilpatrick Journal: FASEB J Date: 2019-12-23 Impact factor: 5.191